The spectrum of vaccine therapies for patients with glioblastoma multiforme

Current Treatment Options in Oncology

Volumn 13, Issue 4, 2012, Pages 437-450

  Aguilar, Laura K ^a   Arvizu, Mariel ^a   Aguilar Cordova, Estuardo ^a   Chiocca, E Antonio ^b  

^a Advantagene Inc   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Glioblastoma; Glioblastoma multiforme; Immunotherapy; Malignant gliomas; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR THYMIDINE KINASE; ALPHA TYPE 1 POLARIZED DENDRITIC CELL VACCINE; AUTOLOGOUS BRAIN TUMOR STEM CELL MESSENGER RNA; AUTOLOGOUS FORMALIN FIXED TUMOR VACCINE; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CARMUSTINE; CORTICOSTEROID; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII ANTIGEN PEPTIDE VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; HLA A2 RESTRICTED PEPTIDE VACCINE; IMA 950; IMIQUIMOD; INTERLEUKIN 1BETA; KEYHOLE LIMPET HEMOCYANIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEPTIDE VACCINE; PICIBANIL; PLACEBO; PROSTAGLANDIN E2; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARCINOGENESIS; CELL THERAPY; CIRCUMORAL PARESTHESIA; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DIRECT TUMOR CELL IMMUNIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG IMPLANT; DRUG INDICATION; DRUG SAFETY; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FAMILY HISTORY; FLU LIKE SYNDROME; GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY; GENE MEDIATED IMMUNIZATION; GENE THERAPY; GENE TRANSFER; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INJECTION SITE REACTION; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; KILLED AUTOLOGOUS TUMOR CELL; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUROTOXICITY; NONHUMAN; PEPTIDE IMMUNIZATION; PROGRESSION FREE SURVIVAL; REVIEW; SKIN TINGLING; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ACYCLOVIR; AUTOANTIGENS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; SIGNAL TRANSDUCTION; VALINE;

EID: 84870816970     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0208-2     Document Type: Review

References (43)

1. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101:2293-9.
2. Kohler B, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Canc Inst. 2011;103:714-36.
3. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
4. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2011;59:1169-80.
5. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol. 2011;2011:732413.
6. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
7. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-53.
8. Sathornsumetee S, et al. Molecularly targeted therapy for malignant glioma. Cancer. 2007;110:13-24.
9. Hegi ME, et al. Correlation of O6-methylguanine methyltransferase (MGMT)promotermethylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189-99.
10. Noushmehr H, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Canc Cell. 2010;17:510-22.
11. Verhaak RGW, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Canc Cell. 2010;17:98-110.
12. Yang I, et al. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 2010;17:1381-5.
13. Heimberger AB, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14:5166-72.
14. Jordan JT, et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Canc Immunol Immunother. 2008;57:123-31.
15. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
16. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
17. Stummer W, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392-401.
18. Sanai N, Polley M-Y, McDermottMW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115:3-8.
19. Kubben PL, et al. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12:1062-70.
20. Walker MD, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-43.
21. Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-66.
22. Halperin EC, Bentel G, Heinz ER, Burger PC. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys. 1989;17:1347-50.
23. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
24. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24:1273-80.
25. Chen AM, et al. Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007;69:825-30.
26. Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
27. Ahluwalia MS. American Society of Clinical Oncology 2011 CNS tumors update. Expert Rev Anticancer Ther. 2011;11:1495-7.
28. Westphal M, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88.
29. Norden D, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-87.
30. Perry J, Chambers A, Spithoff K, Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol. 2007;14:189-94.
31. Friedman HS, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-40.
32. Prins RM, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17:1603-15.
33. Wheeler CJ, et al. Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients. Cancer Res. 2008;68:5955-64.
34. De Vleeschouwer S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14:3098-104.
35. Yamanaka R, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160-7.
36. Ryoma Y, et al. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res. 2004;24:3295-301.
37. Okada H, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrentmalignant glioma. J Clin Oncol. 2011;29:330-6.
38. Zhu X, et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5:10.
39. Muragaki Y, et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg. 2011;115:248-55.
40. Sampson JH, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:4722-9.
41. Sampson JH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13:324-33.
42. Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem. 2011;112:1969-77.
43. Chiocca EA, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol. 2011;29:3611-9.